Asset profile
SLS-002 · SLS-002
Small molecule
Evidence outlook · lead readout
NCT04669665 · Depressive Disorder, Major, Suicidal
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
NCT04669665: The study included a randomized, double-blind, placebo-controlled component, but also had an open-label single-group component, and the registry does not report the primary MADRS comparison or its result. Because no results are available, the evidence remains limited despite the controlled design in Part 2.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.